[1] LLOVET J M, ZUCMAN-ROSSI J, PIKARSKY E, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 14(2):16018. [2] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. [3] 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10):721-727. [4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. [5] QIN SK, CHENG Y, LIANG J, et al.Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma:A Subgroup Analysis of the EACH Study[J]. Oncologist, 2014, 19(11):1169-1178. [6] CHENG AL, KANG YK, CHEN ZD, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34. [7] LLOVET J M, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390. [8] KUDO M, FINN R S, QIN SK, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173. [9] BRUIX J, QIN SK, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2017, 389(10064):56-66. [10] ABOU-ALFA G K, MEYER T, CHENG AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]. N Engl J Med, 2018, 379(1):54-63. [11] ZHU A X, KANG Y K, YEN C J, et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2):282-296. [12] BISHOP G A, BERTOLINO P D, BOWEN D G, et al.Tolerance in liver transplantation[J]. Best Pract Res Clin Gastroenterol, 2012, 26(1):73-84. [13] SHI F, SHI M, ZENG Z, et al.PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients[J]. Int J Cancer, 2011, 128(4):887-896. [14] KUREBAYASHI Y, OJIMA H, TSUJIKAWA H, et al.Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J]. Hepatology, 2018, 68(3):1025-1041. [15] MELLMAN I, COUKOS G, Dranoff G.Cancer immunotherapy comes of age[J]. Nature, 2011, 480(7378):480-489. [16] PARRY R V, CHEMNITZ J M, FRAUWIRTH K A, et al.CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J]. Mol Cell Biol, 2005, 25(21):9543-9553. [17] FUKUMURA D, KLOEPPER J, AMOOZGAR Z, et al.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5):325-340. [18] CHEN D S, IRVING B A, HODI F S.Molecular Pathways:Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1[J]. Clin Cancer Res, 2012, 18(24):6580-6587. [19] TABCHI S, MESSIER C, BLAIS N.Immune-mediated respiratory adverse events of checkpoint inhibitors[J]. Curr Opin Oncol, 2016, 28(4):269-277. [20] EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502. [21] SANGRO B, PARK J W, DELA CRUZ C M, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients(pts) with advanced hepatocellular carcinoma(HCC):CheckMate-459[J]. J Clin Oncol, 2016, 34(15 suppl):TPS4147-TPS4147. [22] LEE M S, RYOO BY, HSU CH, et al.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140):an open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6):808-820. [23] GALLE P R, FINN R S, QIN SK, et al.Patient-reported outcomes(PROs) from the Phase III IMbrave150 trial of atezolizumab(atezo) + bevacizumab(bev) vs sorafenib(sor) as first-line treatment(tx) for patients(pts) with unresectable hepatocellular carcinoma(HCC)[J]. J Clin Oncol, 2020, 38(4 suppl): 476-476. [24] FINN R S, QIN SK, IKEDA M, et al.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905. [25] IKEDA M, SUNG M W, KUDO M, et al.A phase 1b trial of lenvatinib(LEN) plus pembrolizumab(PEM) in patients(pts) with unresectable hepatocellular carcinoma(uHCC)[J]. J Clin Oncol, 2018, 36(15 suppl):4076-4076. [26] LLOVET J M, KUDO M, CHENG A L, et al. Lenvatinib(len) plus pembrolizumab(pembro) for the first-line treatment of patients(pts) with advanced hepatocellular carcinoma(HCC):Phase 3 LEAP-002 study[J]. J Clin Oncol, 2019, 37(15 suppl):TPS4152-TPS4152. [27] ZHANG W. Preliminary results of sintilimab plus different dose of IBI305(anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma:A phase Ib study, ASCO Virtual Scientific Program, F, 2020[C]. American Society of Clinical Oncology. [28] KELLEY R K, SANGRO B, HARRIS W P, et al.Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab(T) in combination with durvalumab(D) for patients(pts) with advanced hepatocellular carcinoma(aHCC)[J]. J Clin Oncol, 2020, 38(15 suppl):4508-4508. [29] QIN S, CHEN Z, LIU Y, et al.A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019, 37(15 suppl):4074-4074. [30] ZHU A X, FINN R S, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952. [31] FINN R S, RYOO B-Y, MERLE P, et al.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240:A Randomized, Double-Blind, Phase III Trial[J]. J Clin Oncol, 2020, 38(3):193-202. [32] QIN S K, REN Z G, MENG Z Q, et al. A randomized multicenter phase 2 study to evaluate SHR-1210(PD-1 Antibody) in subjects with advanced hepatocellular carcinoma(HCC) who failed or were intolerant to prior systemic treatment[C].2018, ESMO:LBA27:1-16. [33] WANG F, QIN S K, SUN X C, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab:data derived from a multicenter phase 2 trial[J]. J Hemato Oncol, 2020, 13(1):47. [34] XU J M, ZHANG Y, JIA R, et al.Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer:An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res. 2019, 25(2):515-523. [35] XU J, SHEN J, GU S, et al. Camrelizumab(C) in combination with apatinib(A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial[J]. Clin Cancer Res, 2020:clincanres.2571.2020. [36] YAU T, KANG YK, KIM TY, et al.Nivolumab(NIVO) + ipilimumab(IPI) combination therapy in patients(pts) with advanced hepatocellular carcinoma(aHCC):Results from CheckMate 040[J]. J Clin Oncol, 2019, 37(15 suppl):4012-4012. [37] SPOSITO C, MARIANI L, GERMINI A, et al.Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation:A case-control study[J]. J Hepatol, 2013, 59(1):59-66. [38] PFEIFFENBERGER J, KOSCHNY R, HOFFMANN K, et al.Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation[J]. Langenbecks Arch Surg, 2013, 398(8):1123-1128. [39] AU P K, HO CHOK K S. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma:A proposed management algorithm[J]. World J Gastroenterol, 2018, 24(45):5081-5094. [40] VARKARIS A, LEWIS D W, NUGENT F W.Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma[J]. Am J Gastroenterol, 2017, 112(12):1895-1896. [41] DE TONI E N, GERBES A L. Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient[J]. Gastroenterology, 2017, 152(6):1631-1633. [42] FRIEND B D, VENICK R S, MCDIARMID S V, et al.Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma[J]. Pediatr Blood Cancer, 2017, 64(12) . [43] RAMMOHAN A, REDDY M S, FAROUK M, et al.Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet[J]? Hepatology, 2018, 67(3):1166-1168. [44] KASEB A O, CAO H S T, MOHAMED Y I, et al. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol, 2020, 38(15 suppl):4599-4599. [45] SUN H-C, ZHU X-D, HUANG C, et al.Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection[J]. J Clin Oncol, 2020, 38(15 suppl):e16690. [46] PINATO D J, COLE T, BENGSCH B, et al.A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC):PETAL[J]. Ann Oncol, 2019, 30(5 suppl):v253-v324. [47] OGASAWARA S, LLOVET J, EL-KHOUEIRY A, et al.LEAP-012:A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization(TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Ann Oncol, 2020. [48] SANGRO B, KUDO M, QIN S, et al.A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma:EMERALD-1[J]. Ann Oncol, 2020. [49] DHARMAPURI S, ÖZBEK U, LIN J Y, et al.Predictive value of neutrophil-lymphocyte ratio(NLR) and platelet-lymphocyte ratio(PLR) In hepatocellular carcinoma(HCC) patients treated with nivolumab(N)[J]. Ann Oncol, 2019, 30:v285-v286. [50] LOSIC B, CRAIG A J, VILLACORTA-MARTIN C, et al.Intratumoral heterogeneity and clonal evolution in liver cancer[J]. Nat Commun, 2020, 11(1):291. [51] HUANG M L, HE M H, GUO Y, et al.The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas[J]. Clin Cancer Res, 2020, 26(18):4947-4957. [52] BERRAONDO P, OCHOA M C, OLIVERA I, et al.Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation[J]. Cancer Discovery, 2019, 9(8):1003-1005. [53] SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al.Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features[J]. Gastroenterology, 2017, 153(3):812-826. [54] HARDING J J, NANDAKUMAR S, ARMENIA J, et al.Prospective Genotyping of Hepatocellular Carcinoma:Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies[J]. Clin Cancer Res, 2019, 25(7):2116-2126. |